Cargando…
The clinical course of symptomatic deep vein thrombosis after 3 months of anticoagulant therapy using fondaparinux/edoxaban or fondaparinux/vitamin K antagonist
BACKGROUND: For the management of venous thromboembolism (VTE), providing anticoagulant therapy within the therapeutic range has been a major challenge, as conventional therapy with unfractionated heparin (UFH) and vitamin K antagonist (VKA) requires frequent laboratory monitoring and dose adjustmen...
Autores principales: | Shimizu, Kazuhiro, Iiduka, Takuo, Sato, Shuji, Kiyokawa, Hajime, Nakagami, Takahiro, Mikamo, Hiroshi, Kawazoe, Masayo, Takahashi, Mao, Noro, Mahito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827747/ https://www.ncbi.nlm.nih.gov/pubmed/29503557 http://dx.doi.org/10.2147/TCRM.S153517 |
Ejemplares similares
-
Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report
por: Shimizu, Kazuhiro, et al.
Publicado: (2016) -
A Case Demonstrating the Cardio-Vascular Interaction by a New Cardio-Ankle Vascular Index During the Treatment of Concentric Hypertrophy
por: Shimizu, Kazuhiro, et al.
Publicado: (2019) -
The Fondaparinux Paradox: Fondaparinux-Related Heparin-induced Thrombocytopenia
por: Vadi, Sonali, et al.
Publicado: (2018) -
Fondaparinux-associated Thrombocytopenia
por: Malik, Jahanzeb, et al.
Publicado: (2021) -
Effect of nicorandil administration on cardiac burden and cardio-ankle vascular index after coronary intervention
por: Sato, Shuji, et al.
Publicado: (2020)